Short answer
Editas Medicine, Inc. (EDIT) filed an 8-K current report with the SEC on March 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 earnings released March 9, 2026: financial details in Exhibit 99.1.
Editas Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 earnings released March 9, 2026: financial details in Exhibit 99.1
- EDIT is a clinical-stage gene editing biotech; results signal cash runway and pipeline progress critical to investor thesis
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Editas Medicine, Inc. 8-K filings
Get the next EDIT 8-K as it lands
Follow EDIT for push alerts, or ask the research agent what this filing means.